Filing Flows › Apyx Medical (APYX) › Q3 2026
Apyx Medical (APYX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Apyx Medical (APYX) reported revenue of $14.0M for the third quarter 2026 (Q3 2026), +9% from a year earlier and +1% from the quarter before. Operating margin was -4.1%, net loss $1.8M (12.9% of revenue).
Apyx Medical, Q3 2026: revenue $14.0M (+9% year over year), operating margin -4.1%, net loss $1.8M, operating cash flow −$1.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.0M | +1% | +9% |
| Operating profit | −$571K | — | — |
| Net earnings | −$1.8M | — | — |
| Operating cash flow | −$1.6M | — | — |
What changed
Revenue was $14.0M in Q3 2026, up 9% year over year and up 1% from the previous quarter.
Gross margin was 64.2%, down 0.3 points from Q3 2025. Operating costs exceeded revenue by $571K, an operating margin of -4.1%. Operating expenses grew 5% against revenue growth of 9%. The quarter ended with a net loss of $1.8M, narrower than the previous quarter's $3.1M loss. Minority interests bore $21K of it: to shareholders the quarter was a loss of $1.8M. Net interest and other expense of $1.1M was the main reason.
Operating cash flow was −$1.6M. Non-cash charges added back $187K of depreciation and amortization and $753K of share-based compensation. Working capital and other items used $768K. Capital expenditures of $265K exceeded it, leaving free cash flow of −$1.9M.
Questions
What was Apyx Medical's revenue in the third quarter 2026?
Apyx Medical (APYX) reported revenue of $14.0M for the third quarter 2026 (Q3 2026), +9% from a year earlier and +1% from the quarter before.
Was Apyx Medical profitable in the third quarter 2026?
Operating loss was $571K (-4.1% of revenue) and net loss $1.8M.
Source: Apyx Medical 10-Q on SEC EDGAR.